ClinicalTrials.gg
CompletedNCT01959516Updated Apr 15, 2016Results posted

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

A Phase 4 interventional study of Glycopyrronium and Tiotropium in COPD, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-04-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
39th of 73
124 · median 152
Started
2014
with 8 others
Phase 4
11 of 73
1 open now
Registered
36th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 39th largest by enrollment, is one of 9 that started in 2014, is one of 11 in phase 4, and was the 36th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study purpose is to further study the profiles of glycopyrronium (NVA237) and tiotropium during the first hours after dosing and their impact on pulmonary function, COPD symptoms and ability to perform daily activities by the patient.

Read the detailed description

Randomized, multicenter, blinded, two-period cross-over design. Each treatment will last 28 days. All patients will receive both treatments in a cross-over design, with a wash-out period of 14-19 days in between. The total duration of the study for each patient is approximately 70 days (from randomization) plus 30 days of safety follow-up.

03

Conditions studied

  • COPD

Keywords

  • COPD, early morning symptoms
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults aged ≥ 40 years.
  • Co-operative outpatients with a clinical diagnosis of moderate to severe confirmed by spirometry according to GOLD criteria 2013 and including all of the following: a) Current or ex-smokers who have a smoking history of at least 10 pack years (e.g.10 pack years = 1 pack /day x 10 years or ½ pack/day x 20 years). An ex-smoker may be defined as a subject who has not smoked for ≥ 6 months at Screening. b) Patients with airflow limitation indicated by a post-bronchodilator \< 80% and ≥ 40% of the predicted normal value at Visit 2 (Post- bronchodilator refers to within 10-15 min of inhalation of 400 µg (4x100 µg) of salbutamol). c) .Post-bronchodilator FEV1/FVC \< 0.7 at Visit 2 (Post- bronchodilator refers to within 10-15 min of inhalation of 400 µg (4x100 µg) of salbutamol).
  • Patients with a COPD Assessment Test (CAT) score ≥ 10 at Visit 2.

Exclusion criteria

Exclusion criteria:

  • Patients who have had a exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to Visit 1. In the event of an exacerbation occurring during the Screening period (Visits 1-2), the patient must be discontinued from the study. The patient may be re-enrolled once the inclusion/exclusion criteria are met. Only one re-enrollment is allowed.
  • Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Patients who develop a respiratory tract infection between Visit 1 and Visit 2 must discontinue from the trial, but may be permitted to re-enrol at a later date once the inclusion/exclusion criteria have been met. Only one re-enrollment is allowed.
  • Patients on any long-acting bronchodilator therapy. Those patients may enter the study after bronchodilator withdrawal during a 10-day (only rescue salbutamol allowed as bronchodilator therapy during wash-out). Patients on fixed combination of long acting β2-agonists/inhaled (LABA/ICS) therapy before screening must be switched to the equivalent dose of ICS monotherapy and salbutamol as rescue.
  • Patients receiving any other prohibited COPD-related medications specified in Table 5-1 must undergo the required wash-out period prior to Visit 2.
  • Patients who have had a clinical history of asthma.
  • Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis or bronchiectasis.
  • Patients with alpha-1-antitrypsin deficiency.
  • Patients with for LAMA treatment including medical history of symptomatic prostatic hypertrophy, bladder neck obstruction, narrow-angle glaucoma and severe renal impairment (estimated below 30 ml/min/1.73 m2) documented in the previous 6 months.
  • Patients with a history of unstable cardiovascular disease or arrhythmias including atrial fibrillation/flutter or long syndrome or whose resting QTcF (calculated according to Fridericia QT correction formula preferred, but Bazett acceptable) is prolonged (≥ 450 msec for males and ≥ 460 msec for females) at screening (Visit 1) or baseline (Visit 2, baseline 1).
  • Concomitant use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study.
  • Patients contraindicated for treatment with, or having a history of reactions/ to any of the following inhaled drugs, drugs of a similar class or any component thereof: -anticholinergic agents - long and short acting 2 agonists -sympathomimetic amines - of the trial medication (lactose monohydrate and/or magnesium estearate)
  • Patients whose (BMI) is less than 15 or greater than 40 kg/m2.
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .

Other exclusion criteria may apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Sequence A ⇒ B

    Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.

    Drug: Glycopyrronium · Drug: Tiotropium · Drug: Placebo to glycopyrronium · Drug: Placebo to tiotropium

  • Experimental
    Sequence B ⇒ A

    Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.

    Drug: Glycopyrronium · Drug: Tiotropium · Drug: Placebo to glycopyrronium · Drug: Placebo to tiotropium

Interventions

  • Glycopyrronium capsule for inhalation once per day via SDDPI

  • Tiotropium capsule for inhalation once per day via HandiHaler® device

  • DrugPlacebo to glycopyrronium

    Placebo to glycopyrronium capsule for inhalation once per day via SDDPI

  • DrugPlacebo to tiotropium

    Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1) AUC0-4h After First Dose of Treatment.

    Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) will measured via spirometry and calculated from 0 to 4 hours post-dose on day 1 of study treatment.

    Time frame: Day 1

Secondary outcomes

  1. Comparison of Glycopyrronium QD Versus Tiotropium QD on Symptoms Outcome

    Comparison of symptoms outcome between glycopyrronium QD versus tiotropium QD will be conducted via the PROMorning COPD Symptoms questionnaire. This questionnaire will be completed by participants at waking-up, pre-inhalation of study treatment (at home), and they will complete Part 2 of PRO-Morning COPD Symptoms questionnaire at site, 3hours post-inhalation of study treatment. The PRO-Morning COPD Symptoms Questionnaire is a self-administered patient reported outcome (PRO) instrument developed by the sponsor to evaluate patients' experience of early morning symptoms of COPD. The questionnaire consists of two parts : predose and postdose. Each part has 6 questions and for each question a scale of 0 to 10 can be reached. For the predose and postdose part of the questionnaire you will have then each a total score of 0-60 by adding the sub-scores for each question, higher scores represent worse severity of COPD morning symptoms

    Time frame: day 1 (baseline) and week 4

07

Results

Posted Apr 15, 2016

Participant flow

A total of 126 patients were randomized to one of the two treatment sequences in a ratio of 1:1. Due to misrandomization, two patients did not receive at least one dose of the study treatment. Both, safety and ITT population included 124 patients.

Epoch 1
Participant flow — Epoch 1
MilestoneGlycopyrronium First, Then Tiotropium"Tiotropium First, Then Glycopyrronium
Started6363
Safety population6262
Itt population6262
Completed5358
Not completed105
Withdrew: Adverse event41
Withdrew: Unsatisfactory therapeutic effect10
Withdrew: Subject withdrew consent32
Withdrew: Administrative problems10
Withdrew: Use of prohibited treatment10
Withdrew: Moderate or severe copd exacerbation01
Withdrew: Protocol deviation01
Epoch 2
Participant flow — Epoch 2
MilestoneGlycopyrronium First, Then Tiotropium"Tiotropium First, Then Glycopyrronium
Started6363
Completed6162
Not completed21
Withdrew: Unsatisfactory therapeutic effect10
Withdrew: Subject withdrew consent10
Withdrew: Moderate or severe copd exacerbation01

Outcome measures

PrimaryForced Expiratory Volume in 1 Second (FEV1) AUC0-4h After First Dose of Treatment.

Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) will measured via spirometry and calculated from 0 to 4 hours post-dose on day 1 of study treatment.

Time frame:
Day 1
Reported as:
Least squares mean · Liters*hours
Forced Expiratory Volume in 1 Second (FEV1) AUC0-4h After First Dose of Treatment.
Liters*hoursGlycopyronium From Sequence A to B and Sequence B to ATiotropium From Sequence A to B and Sequence B to A
Forced Expiratory Volume in 1 Second (FEV1) AUC0-4h After First Dose of Treatment.1.7432 ± 0.51711.7132 ± 0.5175
Statistical analysis
  • Glycopyronium From Sequence A to B and Sequence B to A vs Tiotropium From Sequence A to B and Sequence B to A · Mixed Models Analysis · p = 0.0250
SecondaryComparison of Glycopyrronium QD Versus Tiotropium QD on Symptoms Outcome

Comparison of symptoms outcome between glycopyrronium QD versus tiotropium QD will be conducted via the PROMorning COPD Symptoms questionnaire. This questionnaire will be completed by participants at waking-up, pre-inhalation of study treatment (at home), and they will complete Part 2 of PRO-Morning COPD Symptoms questionnaire at site, 3hours post-inhalation of study treatment. The PRO-Morning COPD Symptoms Questionnaire is a self-administered patient reported outcome (PRO) instrument developed by the sponsor to evaluate patients' experience of early morning symptoms of COPD. The questionnaire consists of two parts : predose and postdose. Each part has 6 questions and for each question a scale of 0 to 10 can be reached. For the predose and postdose part of the questionnaire you will have then each a total score of 0-60 by adding the sub-scores for each question, higher scores represent worse severity of COPD morning symptoms

Time frame:
day 1 (baseline) and week 4
Reported as:
Least squares mean · Scores on a scale
Comparison of Glycopyrronium QD Versus Tiotropium QD on Symptoms Outcome
Scores on a scaleGlycopyronium From Sequence A to B and Sequence B to ATiotropium From Sequence A to B and Sequence B to A
3h post-dose (Day 1)9.7068 ± 8.810.3974 ± 8.1
3h post-dose (Week 4)10.4641 ± 8.810.3193 ± 9.3
Statistical analysis
  • Glycopyronium From Sequence A to B and Sequence B to A vs Tiotropium From Sequence A to B and Sequence B to A · Mixed Models Analysis · p = 0.1439

Adverse events

Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glycopyronium From Sequence A to B and Sequence B to A—2/124 (1.6%)17/124 (13.7%)
Tiotropium From Sequence A to B and Sequence B to A—2/124 (1.6%)12/124 (9.7%)
Most frequent serious events
Most frequent serious events
EventGlycopyronium From Sequence A to B and Sequence B to ATiotropium From Sequence A to B and Sequence B to A
PneumoniaInfections and infestations1/1240/124
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1241/124
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1240/124
PleurisyRespiratory, thoracic and mediastinal disorders0/1241/124
Most frequent other events
Showing 10 of 33
Most frequent other events
EventGlycopyronium From Sequence A to B and Sequence B to ATiotropium From Sequence A to B and Sequence B to A
NasopharyngitisInfections and infestations3/1240/124
CoughRespiratory, thoracic and mediastinal disorders2/1240/124
Bundle branch block leftCardiac disorders1/1240/124
Bundle branch block rightCardiac disorders1/1240/124
Cystoid macular oedemaEye disorders1/1240/124
Abdominal painGastrointestinal disorders0/1241/124
ConstipationGastrointestinal disorders0/1241/124
DiarrhoeaGastrointestinal disorders0/1241/124
Chest painGeneral disorders0/1241/124
Oedema peripheralGeneral disorders0/1241/124

Baseline characteristics

The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and had at least one post-dose value of FEV1

Age, Continuous
Age, Continuous(Years)All Participants (Intent To Treat Analysis,ITT)
Mean65.7 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants (Intent To Treat Analysis,ITT)
Female37
Male87
08

Study locations

21 sites
  • Novartis Investigative Site
    Geesthacht, Schleswig Holstein 12502, Germany
  • Novartis Investigative Site
    Berlin, 10119, Germany
  • Novartis Investigative Site
    Berlin, 12099, Germany
  • Novartis Investigative Site
    Berlin, 13156, Germany
  • Novartis Investigative Site
    Halle, 06108, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Leipzig, 04275, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Wiesbaden, 65187, Germany
  • Novartis Investigative Site
    Firenze, FI 50122, Italy
  • Novartis Investigative Site
    Milano, MI 20138, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Barcelona, Cataluña 08026, Spain
  • Novartis Investigative Site
    Lugo, Galicia 27003, Spain
  • Novartis Investigative Site
    Zaragoza, 50009, Spain
  • Novartis Investigative Site
    Blackpool, FY3 7EN, United Kingdom
  • Novartis Investigative Site
    Bradford, BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB7 5JD, United Kingdom
  • Novartis Investigative Site
    Cardiff, CF5 4AD, United Kingdom
  • Novartis Investigative Site
    Watford, WD25 7NL, United Kingdom
  • Novartis Investigative Site
    Wishaw, ML2 0DP, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2013
First posted
Oct 10, 2013
Start
Feb 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Apr 15, 2016
Last update
Apr 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01959516
Responsible party
Sponsor
First posted
Oct 10, 2013
Start date
Feb 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Apr 15, 2016
Last update
Apr 15, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Tiotropium

Start the discussion